Study of the effect of anxiolytic GML-1 on the activity of cytochrome CYP2C9 and CYP1A2 isoforms

Resume. Effects of GML-1 compound on activity of isoforms CYP2C9 and CYP1A2 of cytochrome P450 using marker drugs losartane and caffeine in experiments on rats were studied. GML-1 in a dose 10 mg/kg of 10 times higher than the maximum effective anxiolytic dose 1 mg / kg (intraperitoneal administrati...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Фармакокинетика и Фармакодинамика
المؤلفون الرئيسيون:	O. G. Gribakina, R. V. Shevchenko, P. O. Bochkov, A. A. Novitskiy, A. A. Litvin, G. B. Kolyvanov, V. P. Zherdev
التنسيق:	مقال
اللغة:	الروسية
منشور في:	LLC “Publisher OKI” 2019-02-01
الموضوعات:	гмл-1 cyp2c9 cyp1a2 лозартан кофеин метаболическое отношение межлекарственное взаимодействие gml-1 losartane caffeine metabolic ratio drug-drug interaction
الوصول للمادة أونلاين:	https://www.pharmacokinetica.ru/jour/article/view/92

مواد مشابهة

Tropoxine in the effective dose does not affect on activity of CYP2С9 and CYP1А2 isoforms of cytochrome P450 in rats
حسب: V. P. Zherdev, وآخرون
منشور في: (2017-11-01)

Pharmacokinetic interaction of drugs, the metabolisable cytochrome P450 isoenzyme CYP2C9
حسب: O. G. Gribakina, وآخرون
منشور في: (2020-04-01)

Pogostone inhibits the activity of CYP3A4, 2C9, and 2E1 in vitro
حسب: Guiying Zhang, وآخرون
منشور في: (2021-01-01)

CYP2C8 and CYP2C9 mRNA expression profile in the human fetus
حسب: Maria eJohansson, وآخرون
منشور في: (2014-03-01)

The impact of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin dose requirement in Saudi patients
حسب: Salha Jokhab, وآخرون
منشور في: (2025-04-01)

Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus
حسب: Sabina Semiz, وآخرون
منشور في: (2010-11-01)

The Effect of Flavonoid Aglycones on the CYP1A2, CYP2A6, CYP2C8 and CYP2D6 Enzymes Activity
حسب: Mirza Bojić, وآخرون
منشور في: (2019-09-01)

Association between CYP2C9 and CYP2C19 Polymorphism, Metabolism, and Neurotoxicity after Administration of Phenytoin: A Systematic Review
حسب: Rizka Mardhiani, وآخرون
منشور في: (2023-12-01)

In vitro inhibitory effects of kaempferitrin on human liver cytochrome P450 enzymes
حسب: Ning Zhang, وآخرون
منشور في: (2019-01-01)

Descriptors of Cytochrome Inhibitors and Useful Machine Learning Based Methods for the Design of Safer Drugs
حسب: Tyler C. Beck, وآخرون
منشور في: (2021-05-01)

POLYMORPHISMS OF THE CYP1A1, CYP1A2, CYP19, AND SULT1A1 GENES ARE NOT ASSOCIATED WITH INFERTILITY IN WOMEN WITH GENITAL ENDOMETRIOSIS
حسب: LARISA N. Danilova, وآخرون
منشور في: (2018-09-01)

Establishment of Acenocoumarol Pharmacogenetic Algorithm Including CYP2C9 and VKORC1 Genotypes in Bulgarian Patients Treated with Coumarin Anticoagulants
حسب: Tzveova R., وآخرون
منشور في: (2025-06-01)

Distribution of polymorphisms in the CYP2C9 gene and CYP2C19/CYP2C9 haplotypes among Venezuelan populations
حسب: Sara Flores-Gutiérrez, وآخرون
منشور في: (2017-02-01)

Biochemical markers and cells count in peripheral blood in patients with tuberculosis according to CYP2C9 genotype
حسب: P. B. Antonenko
منشور في: (2014-04-01)

Potential Metabolic Drug–Drug Interaction of Citrus aurantium L. (Rutaceae) Evaluating by Its Effect on 3 CYP450
حسب: Lu Zhou, وآخرون
منشور في: (2018-08-01)

CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population
حسب: Merve Arici, وآخرون
منشور في: (2017-03-01)

Genetic CYP2A6 Polymorphism May Worsen Glycohemoglobin Levels: Study among Javanese Indonesian Smokers
حسب: Christine Patramurti, وآخرون
منشور في: (2024-02-01)

Polymorphisms of CYP1A1, CYP1A2, CYP19, and SULT1A1 genes in women with early miscarriage
حسب: I. N. Noskova, وآخرون
منشور في: (2019-12-01)

Polymorphic Variants in Acenocoumarol-Related Genes CYP2C9 and VKORC1 and Their Frequencies in Bulgarian Population
حسب: Tzveova R., وآخرون
منشور في: (2025-09-01)

Effects of ginkgo leaf tablet on the pharmacokinetics of rosiglitazone in rats and its potential mechanism
حسب: Xueting Xing, وآخرون
منشور في: (2022-12-01)

The genetic profiles of CYP1A1, CYP1A2 and CYP2E1 enzymes as susceptibility factor in xenobiotic toxicity in Turkish population
حسب: Merve Arici, وآخرون
منشور في: (2017-02-01)

FREQUENCIES OF POLYMORPHISMS IN THE CYTOCHROME’S P450 GENES OF WARFARIN TRANSFORMATION IN A EUROPEAN POPULATION OF EASTERN SIBERIA
حسب: T. A. Bairova, وآخرون
منشور في: (2018-09-01)

The efficacy and safety of valproic acid medications with controlled active ingredient release in adults in real clinical practice from the position of pharmacokinetic and pharmacogenetic approaches
حسب: P. N. Vlasov, وآخرون
منشور في: (2017-06-01)

Pharmacogenetics and Molecular Ancestry of <i>SLC22A1</i>, <i>SLC22A2</i>, <i>SLC22A3</i>, <i>ABCB1</i>, <i>CYP2C8</i>, <i>CYP2C9</i>, and <i>CYP2C19</i> in Ecuadorian Subjects with Type 2 Diabetes Mellitus
حسب: Adiel Ortega-Ayala, وآخرون
منشور في: (2025-09-01)

Pharmacogenetics of warfarin: A literature review
حسب: Nadezhda V. Izmozherova, وآخرون
منشور في: (2024-11-01)

The Expression of Genes <i>CYP1A1</i>, <i>CYP1B1</i>, and <i>CYP2J3</i> in Distinct Regions of the Heart and Its Possible Contribution to the Development of Hypertension
حسب: Maria L. Perepechaeva, وآخرون
منشور في: (2024-10-01)

Afro-Latin American Pharmacogenetics of <i>CYP2D6</i>, <i>CYP2C9</i>, and <i>CYP2C19</i> in Dominicans: A Study from the RIBEF-CEIBA Consortium
حسب: Mariela Guevara, وآخرون
منشور في: (2024-10-01)

Mathematical modeling of pharmacokinetics and pharmacodynamics of losartan in relation to CYP2C9 allele variants
حسب: Dmitry Babaev, وآخرون
منشور في: (2025-05-01)

Impact of Pomegranate Juice on the Pharmacokinetics of CYP3A4- and CYP2C9-Mediated Drugs Metabolism: A Preclinical and Clinical Review
حسب: Kenza Mansoor, وآخرون
منشور في: (2023-02-01)

DEVELOPMENT AND VALIDATION OF SIMULTANEOUS ASSAY OF SUBSTRATES-MARKERS OF MAIN CYTOCHROME P450 ISOFORMS AND THEIR METABOLITES USING HPLC-MS/MS
حسب: E. A. Egorenkov, وآخرون
منشور في: (2019-01-01)

Impact of <i>CYP2C9, CYP2C19</i> and <i>ABCB1</i> genetic polymorphisms on antiepileptic drug safety and efficacy
حسب: N. A. Galankin, وآخرون
منشور في: (2025-05-01)

Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hyporesponsiveness
حسب: Gustavs Latkovskis, وآخرون
منشور في: (2014-01-01)

CYP3A4*20, CYP3A4*22, CYP2C8*3 and SLCO1B1 as genetic biomarkers to predict peripheral neuropathy induced by paclitaxel and docetaxel: A systematic review
حسب: Angel T. Alvarado, وآخرون
منشور في: (2025-05-01)

Genetic risk factors of cytolysis syndrome in the treatment of recrudescence of chronic cardiovascular diseases
حسب: N. V. Kokh, وآخرون
منشور في: (2018-11-01)

Pharmacogenetic polymorphisms in Brazilian-born, first-generation Japanese descendants
حسب: J.A. Perini, وآخرون
منشور في: (2009-12-01)

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses
حسب: Ping Siu Kee, وآخرون
منشور في: (2023-02-01)

Efficacy of piroxicam for postoperative pain after lower third molar surgery associated with CYP2C8*3 and CYP2C9
حسب: Calvo AM, وآخرون
منشور في: (2017-07-01)

Molecular Ancestry Across Allelic Variants of <i>SLC22A1</i>, <i>SLC22A2</i>, <i>SLC22A3</i>, <i>ABCB1</i>, <i>CYP2C8</i>, <i>CYP2C9</i>, and <i>CYP2C19</i> in Mexican-Mestizo DMT2 Patients
حسب: Adiel Ortega-Ayala, وآخرون
منشور في: (2025-05-01)

Drug–Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes
حسب: Florian Klomp, وآخرون
منشور في: (2020-12-01)

Orphan Cytochromes P450 as Possible Pharmacological Targets or Biomarkers in Breast Cancer
حسب: Barbara Licznerska, وآخرون
منشور في: (2025-08-01)